The 9 analysts offering 12-month price forecasts for Revance Therapeutics Inc have a median target of 26.00, with a high estimate of 55.00 and a low estimate of 22.00. The median estimate represents a +23.46% increase from the last price of 21.06.
The current consensus among 9 polled investment analysts is to Buy stock in Revance Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.81
Reporting Date Nov 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.